Originally published in our sister publication, Clinical Oncology News.
Commonly used to reduce bleeding in patients with hematologic malignancies and severe thrombocytopenia, tranexamic acid (TXA) failed to show this protection in a randomized trial in this setting. Instead, an increased risk for catheter thrombosis associated this preventive strategy with an adverse benefit-to-risk ratio.
TXA has been found to be effective in controlling bleeding in surgery, but “clearly patients with